Royal Bank Of Canada Oyster Point Pharma, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$7.95 - $11.68 $651 - $957	-82 Reduced 2.66%	2,997 $33,000
Q3 2022 Nov 14, 2022	BUY	$4.41 - $8.38 $361 - $687	82 Added 2.74%	3,079 $16,000
Q2 2022 Aug 15, 2022	SELL	$3.6 - $11.2 $2,455 - $7,638	-682 Reduced 18.54%	2,997 $12,000
Q1 2022 May 16, 2022	SELL	$8.58 - $17.65 $13,324 - $27,410	-1,553 Reduced 29.68%	3,679 $42,000
Q4 2021 Feb 14, 2022	BUY	$10.17 - $18.96 $5,908 - $11,015	581 Added 12.49%	5,232 $95,000
Q3 2021 Nov 15, 2021	BUY	$11.67 - $18.07 $33,632 - $52,077	2,882 Added 162.92%	4,651 $55,000
Q2 2021 Aug 16, 2021	BUY	$16.25 - $21.51 $28,746 - $38,051	1,769 New	1,769 $31,000

19K

Ticker OYST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,831,500
Description
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.